Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2025)
Pacira BioSciences (PCRX) posted quarterly Asset Writedowns and Impairment of $16.1 million for Q4 2022, up 1052.43% quarter-over-quarter from $1.4 million in Q4 2011.
Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends
Pacira BioSciences' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $16.1 million for Q4 2022.
- In Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $16.1 million; the TTM figure through Dec 2024 stood at $16.1 million (down 7.98% YoY), while the FY2025 annual figure was $11.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2022 stood at $16.1 million, up from $1.4 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $16.1 million in Q4 2022, with the low at $16.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 14.87 Mn |
| Sep 30, 2025 | 14.87 Mn |
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2011 | 1.40 Mn |
| Dec 31, 2011 | 1.40 Mn |